| 张立新,孙芳初,孙国贵.顺铂联合腹腔持续热灌注治疗胃癌腹腔转移癌性腹水的临床研究[J].中国肿瘤,2013,22(5):413-416. |
| 顺铂联合腹腔持续热灌注治疗胃癌腹腔转移癌性腹水的临床研究 |
| Clinical Study of Cisplatin Combined with Continuous Hyperthermic Peritoneal Perfusion in the Treatment for Metastatic Ascites with Gastric Cancer |
| 投稿时间：2012-11-28 |
| DOI：10.11735/j.issn.1004-0242.2013.05.2012347 |
|
 |
| 中文关键词: 胃癌腹水 温热化疗 顺铂 |
| 英文关键词:metastatic ascites with gastric cancer hyperthermic chemotherapy cisplatin |
| 基金项目: |
|
| 摘要点击次数: 2342 |
| 全文下载次数: 1705 |
| 中文摘要: |
| 摘 要：［目的］ 观察顺铂（DDP）联合持续热灌注治疗胃癌腹腔转移腹水的疗效及不良反应。［方法］ 60例胃癌腹水患者分为顺铂联合腹腔持续热灌注组（治疗组）和单纯顺铂腹腔灌注化疗组（对照组），每组各30例。对两组生存期、控制腹水的近期疗效、不良反应进行观察。［结果］ 治疗组和对照组的中位生存期分别为10.2个月和5.9个月，有效率分别为76.7%和53.3%（P<0.05），治疗组不良反应无加重。［结论］ DDP联合腹腔持续热灌注治疗胃癌腹水，能够提高疗效，延长生存期而不增加不良反应，值得进一步推广。 |
| 英文摘要: |
| Abstract:［Purpose］ To investigate the efficacy and toxicity of cisplatin combined with continuous hyperthermic peritonal perfusion (CHPP) in the treatment for metastatic ascites with gastric cancer-induced peritoneal effusion. ［Methods］ Sixty patients with metastatic ascites were divided into two groups: treatment group (received cisplatin and CHPP) and control group (received cisplatin alone).The survival，short-term response，quality of life and side effects were observed.［Results］ The median survival of the treatment group and control group were 10.2 months and 5.9 months；and the response rates，76.7% and 53.3%(P<0.01)respectively. The incidence rates of side effects were similar between the two groups. ［Conclusions］ Cisplatin combined with CHPP can increase treatment response and improve survival without increasing side effects in patients with metastatic ascites with gastric cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|